D Masin
Overview
Explore the profile of D Masin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
378
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verreault M, Wehbe M, Strutt D, Masin D, Anantha M, Walker D, et al.
J Control Release
. 2015 Nov;
220(Pt A):348-357.
PMID: 26528901
Our laboratory reported that Irinophore C™ (IrC™; a lipid-based nanoparticulate formulation of irinotecan) is effective against an orthotopic model of glioblastoma (GBM) and that treatment with IrC™ was associated with...
2.
Verreault M, Strutt D, Masin D, Anantha M, Waterhouse D, Yapp D, et al.
J Control Release
. 2011 Oct;
158(1):34-43.
PMID: 22001870
Given compelling evidences supporting the therapeutic potential of irinotecan (IRN) for patients with glioblastoma (GBM), the present study evaluated the activity of Irinophore C™ (IrC™), a lipid-based nanopharmaceutical formulation of...
3.
Verreault M, Strutt D, Masin D, Fink D, Gill R, Bally M
Anticancer Res
. 2011 Jul;
31(6):2161-71.
PMID: 21737636
Unlabelled: Glioblastoma (GBM) cell lines expressing red fluorescent proteins were evaluated as a tool for non-invasive imaging of orthotopic tumors. Materials And Methods: mKate2- and mCherry-transduced U251MG GBM lines were...
4.
Johnstone S, Masin D, Mayer L, Bally M
Biochim Biophys Acta
. 2001 Jun;
1513(1):25-37.
PMID: 11427191
Serum proteins, acting as opsonins, are believed to contribute significantly to liposome-macrophage cell association and thus regulate liposome uptake by cells of the mononuclear phagocytic system (MPS). We studied the...
5.
Lim H, Parr M, Masin D, McIntosh N, Madden T, Zhang G, et al.
Clin Cancer Res
. 2000 Dec;
6(11):4449-60.
PMID: 11106266
A tumor model designed to assess liposome-mediated drug delivery to liver has been used in an attempt to better understand the mechanism of activity of liposomal mitoxantrone, a liposomal anticancer...
6.
Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden T
Cancer Res
. 2000 Jul;
60(13):3389-93.
PMID: 10910044
Topotecan was encapsulated in sphingomyelin/cholesterol liposomes using an ionophore-generated proton gradient. After i.v. injection, liposomal topotecan was eliminated from the plasma much more slowly than free drug, resulting in a...
7.
Lim H, Masin D, McIntosh N, Madden T, Bally M
J Pharmacol Exp Ther
. 1999 Dec;
292(1):337-45.
PMID: 10604968
A previous study suggested that drug release is the dominating factor controlling biological activity of liposomal mitoxantrone in tissues where the rate of liposome accumulation is rapid. The studies described...
8.
Lim H, Masin D, Madden T, Bally M
J Pharmacol Exp Ther
. 1997 Apr;
281(1):566-73.
PMID: 9103545
The influence of liposome drug release on the therapeutic activity of encapsulated mitoxantrone was investigated. Liposomes prepared from 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)/cholesterol (Chol) (55:45, molar ratio) or 1,2 dimyristoyl-sn-glycero-3-phosphocholine (DMPC)/Chol (55:45, molar...
9.
Parr M, Masin D, Cullis P, Bally M
J Pharmacol Exp Ther
. 1997 Mar;
280(3):1319-27.
PMID: 9067319
The efficiency of drug accumulation in tumors was measured after intravenous administration of doxorubicin encapsulated in distearoyl phosphatidylcholine/cholesterol liposomes prepared in the presence or absence of 5 mol % polyethylene...
10.
Chang C, Barber L, Ouyang C, Masin D, Bally M, Madden T
Br J Cancer
. 1997 Jan;
75(2):169-77.
PMID: 9010021
Mitoxantrone can be efficiently loaded into large unilamellar vesicles using a transmembrane pH gradient. Release studies indicate that these drug-loaded carriers are highly stable and even after dissipation of the...